Invega Trinza® is the commercial brand name of Paliperidone Palmitate Injection (3M), a long‑acting injectable atypical antipsychotic developed by Janssen. It is the three‑month long‑acting depot ester prodrug of paliperidone, blocking dopamine D2 and serotonin 5‑HT2A receptors to exert antipsychotic effects, releasing drug slowly after intramuscular injection.
Main Indications
Maintenance treatment of schizophrenia in adult patients who have been stabilized with paliperidone palmitate monthly long‑acting injection.
Clinical Research
Global multicenter phase‑III randomized controlled trials demonstrated that 3M paliperidone palmitate injection significantly lowers the risk of schizophrenia relapse versus placebo in clinically stabilized patients;
Long‑term clinical studies proved that this 3M depot formulation improves medication adherence compared with oral antipsychotics and monthly injectable preparations;
Chinese local clinical trials confirmed consistent efficacy and safety outcomes between Chinese subjects and global trial populations.
Common Side Effects
Serious risks: extrapyramidal symptoms, QT‑interval prolongation, neuroleptic malignant syndrome, hyperglycaemia and diabetes‑related events;
Common mild adverse reactions: injection‑site pain, headache, insomnia, somnolence, weight gain, anxiety, upper respiratory tract infection.
Approval Status in China
Original drug Invega Trinza® (Paliperidone Palmitate Injection (3M)) obtained marketing authorization in China in 2021, with specifications including 263 mg. It is currently a prescription drug covered by Chinese medical insurance.
Buy Trinza (Paliperidone Palmitate Injection (3M)) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
